Gilead Sciences stock (US3755581036): Institutional buying and recent price gains

Trek Financial LLC added 13,041 shares of Gilead Sciences on May 13, 2026, amid better-than-expected Q1 results with $2.03 EPS and $6.96B revenue. Shares rose 1.06% to $134.94 on May 12.

Gilead Sciences reported stronger-than-expected first-quarter results on May 13, 2026, with adjusted EPS of $2.03 beating estimates of $1.91 and revenue of $6.96 billion up 4.4% year-over-year, according to MarketBeat as of 05/13/2026. Concurrently, Trek Financial LLC purchased 13,041 shares, signaling institutional interest. The stock gained 1.06% to close at $134.94 on May 12, 2026, on Nasdaq with volume of 6 million shares, per Charles Schwab as of 05/12/2026.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gilead Sciences
• Sector/industry: Biotechnology / Pharmaceuticals
• Headquarters/country: Foster City, USA
• Core markets: US, Europe, Global
• Key revenue drivers: HIV treatments, Oncology
• Home exchange/listing venue: Nasdaq (GILD)
• Trading currency: USD

Gilead Sciences: core business model

Gilead Sciences develops and markets therapies primarily for HIV/AIDS, viral hepatitis, cancer and inflammation. The company focuses on antiviral drugs and oncology treatments, with key franchises in HIV including Biktarvy and Descovy. Its business model relies on innovation in biologics and small molecules, supported by a robust R&D pipeline. Gilead maintains a dividend payout ratio of 44.69%, providing steady returns to shareholders, as noted in recent filings.

Main revenue and product drivers for Gilead Sciences

HIV remains Gilead's largest revenue driver, with products like Biktarvy showing consistent growth. In recent quarters, HIV portfolio sales grew amid stable demand in the US market, which accounts for the majority of revenue. Oncology sales, including Trodelvy, face headwinds from COVID-related declines but show potential in targeted therapies. Q3 2025 product sales reached $7.3 billion, down 2% year-over-year due to lower COVID treatments but up in base business, per earnings call transcript.

Industry trends and competitive position

The biotech sector sees strong demand for HIV and oncology innovations, where Gilead holds a leading position with patented portfolios. Earnings grew 54.5% over the past year, outperforming peers, according to Simply Wall St as of recent data. Competition from generics pressures older drugs, but new launches like lenacapavir for HIV prevention bolster growth. Gilead's US-centric revenue exposes it to domestic healthcare policy shifts, relevant for American investors.

Why Gilead Sciences matters for US investors

Gilead Sciences, listed on Nasdaq, derives over 50% of sales from the US, tying its performance to American healthcare spending and HIV treatment adherence. Institutional moves like Trek Financial's purchase highlight appeal amid market volatility. With a beta of 0.33, the stock offers defensive qualities in biotech downturns, making it noteworthy for US portfolios seeking stability in pharmaceuticals.

Conclusion

Gilead Sciences continues to deliver solid quarterly results and attract institutional buying, with recent EPS beats and share price gains underscoring resilience in HIV and oncology. While oncology faces challenges, HIV strength and pipeline progress support ongoing relevance. Investors track upcoming guidance updates and R&D milestones for further insights into trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.